Alessio Di Landro

Dr. Alessio Di Landro


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
FPFrancesca Romana Prandi
Francesca Romana Prandi
FIFederica Illuminato
Federica Illuminato
CGChiara Galluccio
Chiara Galluccio
MMMarialucia Milite
Marialucia Milite
MMMassimiliano Macrini
Massimiliano Macrini
FBFrancesco Barillà
Francesco Barillà
Left ventricular non-compaction (LVNC) is a rare congenital cardiomyopathy caused by arrest of normal endomyocardial embryogenesis and characterized by the persistence of ventricular hypertrabeculation, isolated or associated to other congenital defects. A 33-year-old male, with family history of sudden cardiac death (SCD), presented to our ER with typical chest pain and was diagnosed with anterior STEMI. Coronary angiography showed an anomalous origin of the circumflex artery from the right coronary artery and a critical stenosis on the proximal left anterior descending artery, treated with primary percutaneous coronary intervention. The echocardiogram documented left ventricular severe dysfunction with lateral wall hypertrabeculation, strongly suggestive for non-compaction, confirmed by cardiac MRI. At 3 months follow up, for the persistence of the severely depressed EF (30%) and the family history for SCD, the patient underwent subcutaneous ICD (sICD) implantation for primary prevention. To the best of our knowledge, this is the first case of LVNC associated with anomalous coronary artery origin and STEMI reported in the literature. Arrhythmias are common in LVNC due to endocardial hypoperfusion and fibrosis. sICD overcomes the risks of transvenous ICD, and it is a valuable option when there is no need for pacing therapy for bradycardia, cardiac resynchronization therapy and anti-tachycardia pacing.

14 August 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FEFrancesca D Errico
Francesca D Errico
FRFrancesca Ricci
Francesca Ricci
ALAlessandra Luciano
Alessandra Luciano
FSFrancesco Paolo Sbordone
Francesco Paolo Sbordone
Mario LaudaziMario Laudazi
Mario Laudazi
MCMarcello Chiocchi
Marcello Chiocchi
Background: The sublingual administration of short-acting nitroglycerin (NTG) before coronary computed tomography (CCT) improves the visualization of coronary arteries, causing vasodilatation. The aim of this study was to evaluate whether and how nitroglycerin can influence the concordance between radiologists and cardiologists in the evaluation of vessel stenosis measured in CCT by the former and during the following coronarography by the latter. Methods: We conducted a retrospective analysis of 131 patients who underwent CCT for cardiac symptoms in 2022, followed by coronarography performed six months later because of significant stenosis revealed by the CCT. First, the patients were divided into two groups: an NTG group who received sublingual nitroglycerin before CCT and a non-NTG group who did not because of contraindications. Second, 254 stenoses were measured by two radiologists after CCT and by two interventional cardiologists during the next coronarography; moreover, stenoses were classified on the basis of their location and plaque pattern (calcific, mixed and lipidic). Third, the strength of agreement was evaluated between the two radiologists, between the two cardiologists and finally between the radiologists and cardiologists in order to evaluate whether and how the interdisciplinary discrepancy in stenosis evaluation could change with or without the use of nitroglycerin before CCT and in relation to the different plaque pattern. Results: In the NTG group, the use of nitroglycerine reduced the agreement between radiologists and cardiologists in calcific stenosis but did not change the concordance in the case of mixed or lipidic plaques on the same vessels. Conclusions: The use of sublingual nitroglycerin before CCT may lead to a radiological overestimation of calcific stenosis.

25 June 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
DGDomenico Mario Giamundo
Domenico Mario Giamundo
FBFrancesco Barillà
Francesco Barillà
LBLucy Barone
Lucy Barone
ALAlessio Di Landro
Alessio Di Landro
DSDomenico Sergi
Domenico Sergi
MMMassimo Marchei
Massimo Marchei
Secondary prevention after SCA (acute coronary syndrome) is of paramount importance to reduce the incidence of MACE and improve prognosis in follow-up. The control of avoidable risk factors, lifestyle modifications, but especially careful control of cholesterolemia (with a target of LDL-C